[The availability of only one statin is inadequate].
When looking at the history of the prescription of a new class of drugs e.g. the statin, it is clear that for optimal use with regard to efficacy, areas of indication and safety, the continuous development of new compounds within this class was very advantageous. Competition between compounds is essential for providing best patient care. Thus the availability of only one statin was and continues to be inadequate for this purpose.
Jukema
J W
JW
Leids Universitair Medisch Centrum, afd. Cardiologie, C5-P, Postbus 9600, 2300 RC Leiden. j.w.jukema@lumc.nl
D015195:Drug Design; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000600:supply & distribution* / Q000627:therapeutic use*; D012449:Safety; D016896:Treatment Outcome
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors